01:32am Friday 24 January 2020

Osteoporosis : balancing bone formation and degradation

Researchers from the CNRS, Inserm and the Université de Montpellier and Université Jean Monnet – Saint-Étienne1 have developed a new approach for preventing the destructive activity of osteoclasts without affecting their viability. This involves disrupting their anchorage to the bone, which has been found to be possible using a small chemical compound called C21. This innovative treatment can protect mice from bone loss associated with osteolytic diseases2 such as post-menopausal osteoporosis, rheumatoid arthritis and bone metastasis, without affecting bone formation. This research was published on 3 February 2015 in the journal Nature Communications.

To download the press release: Ostéoporose


1From the Centre de recherche de biochimie macromoléculaire (CRBM) [Centre for Biochemical and Macromolecular Research] (CNRS/Université de Montpellier), Laboratoire d’enzymologie et biochimie structurale (LEBS) [Laboratory of Enzymology and Structural Biochemistry] (CNRS), Institut de recherche en cancérologie de Montpellier (IRCM) [Montpellier Cancer Research Institute] (Inserm/ Université de Montpellier) and Laboratoire de biologie intégrative du tissu osseux [Laboratory of integrative biology of bone tissue] (Inserm/Université Jean Monnet – Saint-Étienne).
2Diseases related to the degradation of bone tissue.


Pharmacological inhibition of Dock5 prevents osteolysis by affecting osteoclast podosome organization while preserving bone formation. Virginie Vives, Gaëlle Cres, Christian Richard, Muriel Busson, Yann Ferrandez, Anne-Gaelle Planson, Mahel Zeghouf, Jacqueline Cherfils, Luc Malaval and Anne Blangy. Nature communications, 3 February 2015. DOI: 10.1038/ncomms7218.

Contact information:

CNRS Researcher l Anne Blangy l T +33 (0)4 34 35 95 08 l anne.blangy@crbm.cnrs.fr
CNRS Press l Alexiane Agullo l T +33 (0)1 44 96 43 90 l alexiane.agullo@cnrs-dir.fr

Share on:

MORE FROM Bones and Muscles

Health news